title: Retinal detachment after bevacizumab.
authors: J Fernando
authors: JF
authors: Arevalo
authors: Juan G
authors: JG
authors: Sanchez
authors: Lucas
authors: L
authors: Saldarriaga
authors: Maria H
authors: MH
authors: Berrocal
authors: Jans
authors: J
authors: Fromow-Guerra
authors: Virgilio
authors: V
authors: Morales-Canton
authors: Lihteh
authors: L
authors: Wu
authors: Mauricio
authors: M
authors: Maia
authors: Mario J
authors: MJ
authors: Saravia
authors: Jose
authors: J
authors: Bareño
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000601:surgery; D018450:Disease Progression; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012163:Retinal Detachment / Q000209:etiology*; D015861:Retinal Neovascularization / Q000188:drug therapy / Q000601:surgery; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab